Department of Dermatology, The Second Xiangya Hospital of Central South University; Hunan Key Laboratory of Medical Epigenomics; Research Unit of Key Technologies of Diagnosis and Treatment for Immune-related Skin Diseases, Chinese Academy of Medical Sciences (2019RU027), 410011 Changsha, Hunan, China.
Department of orthopaedic, Second Xiangya Hospital, Central South University, 410011 Changsha, Hunan, China.
Curr Pharm Biotechnol. 2021;22(11):1501-1510. doi: 10.2174/1389201022666210104121207.
Emerging studies on the predictive value of Small Nucleolar RNA Host Gene 7 (SNHG7) in human neoplasms give evidence of the association of SNHG7 with the human tumor. However, whether SNHG7 can be utilized as a biomarker for carcinoma is still unknown. Therefore, this meta-analysis is aimed to assess the possibility of SNHG7 serving as a tumor biomarker.
11 studies involving 814 cancer patients were retrieved from several databases, including PubMed, Embase, the Cochrane Library, and Web of Science from 1950 to Dec 27, 2019. Data on patient survival and several clinicopathological features were extracted and analyzed.
Evident association between SNHG7 expression and poor Overall Survival (OS) was demonstrated (HR=1.84, 95% CI: 1.42-2.37) and high SNHG7 level was markedly correlated with tumor size (OR=2.01, 95% CI: 1.27-3.19), advanced clinical grade (III/IV) (OR=3.90, 95% CI: 2.63-5.80), Lymphatic Metastasis (LM) (OR=4.53, 95% CI: 2.71-7.55), and Distant Metastasis (DM) (OR=3.52, 95% CI: 2.58-4.80), except age and gender. Subgroup analysis showed that the predictive value of SNHG7 was consistent regardless of follow-up months, tumor location and sample size. Additionally, data from the R2 database also confirmed this association (p < 0.05). Publication bias was evaluated using Begg's and Egger's test.
SNHG7 could serve for a promising biomarker to predict prognosis, progression and metastasis of human solid cancer.
新兴的关于小核仁 RNA 宿主基因 7（SNHG7）在人类肿瘤中的预测价值的研究证据表明，SNHG7 与人类肿瘤有关。然而，SNHG7 是否可以作为癌的生物标志物尚不清楚。因此，本荟萃分析旨在评估 SNHG7 作为肿瘤标志物的可能性。
从多个数据库（包括 PubMed、Embase、Cochrane Library 和 Web of Science）中检索到 11 项涉及 814 名癌症患者的研究，检索时间从 1950 年至 2019 年 12 月 27 日。提取并分析了与患者生存和几个临床病理特征相关的数据。
SNHG7 表达与总体生存（OS）不良显著相关（HR=1.84，95%CI：1.42-2.37），高 SNHG7 水平与肿瘤大小（OR=2.01，95%CI：1.27-3.19）、高级别临床分期（III/IV）（OR=3.90，95%CI：2.63-5.80）、淋巴转移（LM）（OR=4.53，95%CI：2.71-7.55）和远处转移（DM）（OR=3.52，95%CI：2.58-4.80）显著相关，而与年龄和性别无关。亚组分析表明，无论随访时间、肿瘤部位和样本量如何，SNHG7 的预测价值都是一致的。此外，R2 数据库的数据也证实了这种关联（p<0.05）。使用 Begg 和 Egger 检验评估发表偏倚。
SNHG7 可作为预测人类实体癌预后、进展和转移的有前途的生物标志物。
